Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01722240 · ClinicalTrials.gov registry record · Phase 3
Liraglutide in Type 1 Diabetes
A Phase 3 study, sponsored by University at Buffalo.
- Completed
- Registry status
- Phase 3
- Development phase
- 69
- Enrollment target
NCT01722240 is a Phase 3 study that has completed, run by University at Buffalo. The registered enrollment target is 69 participants.
The verdict
NCT01722240, a Phase 3 study, has completed, sponsored by University at Buffalo.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 69 participants
- Enrollment target
Study Summary
The glucose lowering effects of GLP-1 agonists are well established in subjects with type 2 diabetes, however, these have not been studied prospectively in subjects with type 1 diabetes. The investigators have, therefore, designed this study to investigate the central hypothesis that in patients with type 1 diabetes, Liraglutide has a glucose lowering effect. A major secondary objective of this study is to elucidate the mechanisms responsible for its glucose lowering effects and those involved in reducing the insulin dose. The specific aims of this proposal are: Hypothesis 1: Treatment with Liraglutide in patients with type 1 diabetes decreases HbA1c, fasting, postprandial and the overall mean glucose concentrations while decreasing the dose of insulin required. Hypothesis 2: Treatment with Liraglutide in patients with type 1 diabetes decreases basal and postprandial glucagon concentrations and increases basal and postprandial C-peptide concentrations. Hypothesis 3: Treatment with Liraglutide in patients with type 1 diabetes delays gastric emptying.
Interventions
- DRUG Placebo
- DRUG Liraglutide 1.8mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2012-11-01 |
| Est. Completion | 2019-07-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01722240
The ClinicalTrials.gov registry entry for NCT01722240 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University at Buffalo, which has 67 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01722240 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01722240 about?
NCT01722240 is a clinical study titled "Liraglutide in Type 1 Diabetes". The glucose lowering effects of GLP-1 agonists are well established in subjects with type 2 diabetes, however, these have not been studied prospectively in subjects with type 1 diabetes. The investigators have, therefore, designed this study to investigate the central hypothesis that in patients wit...
What is the current status of trial NCT01722240?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 69 participants. The study started on 2012-11-01. Estimated completion is 2019-07-29.
What interventions are being tested in trial NCT01722240?
The interventions under investigation include: Placebo (DRUG), Liraglutide 1.8mg (DRUG).
Who is sponsoring clinical trial NCT01722240?
This trial is sponsored by University at Buffalo, which has 67 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.